Comparability Considerations and Challenges for Expedited Development Programs for Biological Products

• Main Authors: Sarah J. Schrieber, Wendy S. Putnam, Edwin Chiu Yuen Chow, Jacek Cieslak, Yanli Zhuang, Steven W. Martin, Paul Hanson, Frank Maggio, Leslie A. Rivera Rosado
• Format: Article
• Language: English
• Published: Adis, Springer Healthcare 2020-09-01
• Series: Drugs in R&D
• Online Access: https://doi.org/10.1007/s40268-020-00321-4
• ISSN: 1174-5886; 1179-6901

Abstract Expedited development programs for biological products to be used in the treatment of serious conditions bring about challenges because of the compressed clinical development timeframes. As expedited development does not lessen the quality expectations, one challenge is providing adequate chemistry, manufacturing, and control (CMC) information required to support approval of a biological product. In particular, the analytical comparability and, in some cases, pharmacokinetic comparability studies needed to bridge the clinical material to the commercial material could delay submission of applications for life-saving medicines. While there is the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Topic Q5E guidance on assessing comparability of biological products before and after manufacturing changes, specific guidance on the emerging issue of conducting comparability exercises in the face of expedited drug development is lacking. In July 2019, clinical pharmacologists and product quality chemists from the US FDA and industry representatives convened an FDA workshop for a scientific exchange about considerations and challenges around conducting comparability exercises for expedited programs for biological products. This article highlights discussions from the workshop.